natgillin/translations-raw huggingface dataset:
A compound of any one of embodiments 1 to 11, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of depression, bipolar disorder and anxiety in a mammal. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju depresije, bipolarnog poremećaja 1 tjeskobe u sisavaca.
Non-aqueous solvents include alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl oleate. 
Nevodena otapala uključuju alkohole, propilen-glikol, polietilen-glikol, biljna ulja, poput maslinovog ulja, te organske estere, poput etil-oleata.
a series of steps, by the logic processing unit, developing the template that sets the operating limits for the water points that do not have a dedicated connected device integrating a flow rate sensor and of which the supply with water is directly controlled by said flow rate sensor configured by said method. 
• niz koraka (11-5) koji omogućava jedinici za logičku obradu da razrađuje predložak (10) koji postavlja radne granice za vodene točke koje nemaju pripadajući spojeni uređaj koji integrira senzor protoka čijim dovodom vode izravno upravlja navedeni senzor protoka.
The microcapsule composition according to any of previous claims, wherein the diarrhea is selected from the group consisting of diarrhea associated to chemotherapy or associated to abdominal and /or pelvic radiotherapy in the treatment of cancer, diarrhea as one of the symptoms of AIDS, diarrhea associated to acute gastrointestinal graft- versus-host disease, diarrhea associated to ulcerative colitis, collagenous colitis, microscopic colitis, lymphocytic colitis, Crohn's disease, diarrheas of an infectious viral origin and diarrheas of a bacterial origin. 
Oblik mikrokapsule prema bilo kojem od prethodnih zahtjeva, pri čemu se radi o proljevu iz grupe koja obuhvaća proljev povezan s kemoterapijom ili povezan s radioterapijom abdomena i/ili zdjelice u liječenju raka, proljev kao jedan od simptoma AIDS-a, proljev povezan s akutnom gastrointestinalnom bolesti odbacivanja kod transplantacije, proljev povezan s ulceroznim kolitisom, kolagenoznim kolitisom, mikroskopskim kolitisom, limfocitnim kolitisom, Crohnovom bolesti, proljevi infektivnog virusnog porijekla i proljevi bakterijskog porijekla.
calculating the average austenite phase length/width ratio as the numerical average of the austenite phase length/width ratios of the ten measured austenite phase length/width ratios. 
izračunavanje prosječnog omjera duljine i širine austenitne faze iz deset izmjerenih omjera njezine duljine i širine.
The lever arrangement can be connected to a spindle driven by the motor. 
Pri tome je poluga spojena na pogonsko vratilo motora.
The pharmaceutical composition of item 8, wherein the GLP-1R agonist is selected from GLP-1(7-37), GLP-1(7-36)amide, exendin-4, liraglutide, CJC-1131, albugon, albiglutide, exenatide, exenatide-LAR, oxyntomodulin, lixisenatide, geniproside, AVE-0010 (SEQ ID NO: 9), a short peptide with GLP-1R agonistic activity and/or a small organic compound with GLP-1R agonistic activity. 
Farmaceutski pripravak za uporabu prema zahtjevu 8, naznačen time što je agonist GLP-1 R odabran od GLP-1 (7-37), GLP-1 (7-36)amida, eksendina-4, liraglutida, CIC-1131, albugona, albiglutida, eksenatida, eksenatida-LAR, oksintomodulina, liksisenatida, geniprozida, kratkog peptida s aktivnošću agonista GLP-IR i/ili malog organskog spoja s aktivnošću agonista GLP-1R.
Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. 
Farmaceutski pripravci za parenteralnu primjenu uključuju sterilne vodene i nevodene otopine za injiciranje, disperzije, suspenzije ili emulzije kao 1 sterilne praške koji se mogu, prije upotrebe, rekonstituirati u sterilne otopine za injiciranje ili u disperzije.
hydrogen; is optionally substituted alkyl; 
R* je izborno supstituirani alkil;
L is a linker comprising one or more linker components; 
(b) Lje poveznica koja sadrži jedan ili više veznih sastojaka;
A hybridoma comprising a rearranged immunoglobulin light chain gene sequence derived from the mouse of claim 1, the rearranged sequence comprising a hVλ gene segment, a hJλ gene segment operably linked to a mouse Ck gene segment at an endogenous mouse k immunoglobulin light chain locus, wherein at said locus the k intronic enhancer element upstream of the Ck gene (designated Eki) and the 3' k enhancer downstream of the Ck gene (designated Ek3') are maintained, and where the hybridoma expresses an antibody comprising a light chain that comprises a rearranged human Vλ-Jλ sequence and a mouse Ck sequence. 
Hibridom koji se sastoji od preuređene sekvencije gena lakog imunoglobulinskog lanca dobivene iz miša prema zahtjevu 1, preuređene sekvencije koja se sastoji od hVA segmenta gena, hJA segmenta gena funkcionalno povezanog s mišjim CK segmentom gena na mišjem lokusu endogenog lakog x imunoglobulinskog lanca, pri čemu se na spomenutom lokusu održava x element intronskog pojačivača uzlazno od Ck gena (označeno kao EKi1) 1 3'K pojačivač silazno od CK gena, i pri čemu hibridom izražava antitijelo koje se sastoji od lakog lanca koji sadrži preuređenu humanu V2-J2. sekvenciju i mišju Ck sekvenciju.
Threshold value (g) 
Vrijednost praga (g)
In some instances, the sponge is applied to the injury together with a buffer solution, e.g. a bicarbonate solution, e.g. on a gauze. 
Spužva prema zahtjevu 7, naznačena time da se spužva primjenjuje na navedenu ozljedu zajedno s puferskom otopinom, naročito otopinom bikarbonata, poželjno na gazi.
A pharmaceutical composition comprising a compound of formula I having the structure and a pharmaceutically acceptable carrier therefor. 
Farmaceutska kompozicija naznačena time što sadrži spoj formule I i njegov farmaceutski prihvatljiv nosač.
Alternatively, the keto-ester (AM) can be reacted with hydrazine, followed by alkylation of the pyrazole with benzyl bromide using cesium carbonate as the base in a non-protic solvent such as DMF. 
Alternativno, keto-ester (AM) može HR P20060286 T3 reagirati sa hidrazinom, nakon čega slijedi alkiliranje pirazola sa benzil bromidom uporabom cezij karbonata kao baze u ne-protičnom otapalu poput DMF.
There is no practical way to store the mixture. 
Ne postoji neki praktični način da se smjesa sačuva na skladištu.
Based on these findings the invention relates in one embodiment to a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular domain of prostate-specific membrane antigen (PSMA), the method comprising the steps of: 
HR P20160857 T1 PATENTNI ZAHTJEVI 1. Postupak odabira bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, 1 drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu membranskog antigena specifičnog za prostatu (PSMA), naznačen time što obuhvaća korake:
the said device for filtration or for separation by settling. The device according to claim 10, wherein the feeding means comprise a first restriction for introduction into the second chamber, the pressure drop in the emulsion being created by a second restriction and a third restriction or a valve. 
Uređaj u skladu s patentnim zahtjevom 10, naznačen time, da uređaj za opskrbu sadržava prvo suženje (7) za uvođenje u drugo kućište, a gubitak tlaka u emulziji stvara se preko drugog suženja (15, 38) i trećeg suženja (21, 44) ili ventila (61).
Method according to claim 1, wherein the base unit (3) is screwed to the neck of the container (2) by use of a thread, wherein said thread is equipped with means for preventing release of the base unit (3). 
Sklop za točenje pića prema bilo kojem zahtjevu 7-11, naznačen time, da je šuplje bušilo (11), poravnato sa začepljenim izlazom (9) sklopivog spremnika (2), predviđeno u osnovnoj jedinici (3).
As indicated in FIG. 2, controller 80 and other components could be located remotely from housing 200 (e.g. in the operator cab of the vehicle). 
Kao što je prikazano na slici 2, kontrolor 80 i druge komponente mogu se postaviti na nekoj udaljenosti od kućišta 200 (npr. u kabini operatera na vozilu).
The present invention also provides a method for regulating the fluid balance in a patient having a chronic or acute disease or acute condition. 
PROTUTIJELO PROTIV ADRENOMEDULINA (ADM) ILI FRAGMENT PROTUTIJELA PROTIV ADM ILI OKOSNICA NE-IG PROTIV ADM, NAMIJENJENI REGULIRANJU RAVNOTEŽE TEKUĆINA KOD PACIJENTA S KRONIČNOM ILI AKUTNOM BOLESĆU
The method of Claim 6, characterized in that the coding method uses 5-bit fixed representation. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time što postupak kodiranja upotrebljava 5-bitnu fiksnu reprezentaciju za skup preostalih modova.
A prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression or allergic rhinitis, which comprises the phenylpyrazole derivative or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11 as an active ingredient. 
Derivat fenilpirazola ili njegova farmaceutski prihvatljiva sol prema bilo kojem zahtjevu od 1 do 11 naznačen time da je za upotrebu za sprječavanje ili liječenje demencije, Alzheimerove bolesti, poremećaja hiperaktivnosti sa nedostatkom pažnje, shizofrenije, epilepsije, konvulzija, poremećaja u prehrani, pretilosti, dijabetesa, hiperlipidemije, poremećaja spavanja, narkolepsije, sindroma apneje u snu, poremećaja dnevnog ritma, depresije ili alergijskog Tinitisa.
about 350 µg of the compound from 1 to 2 times daily. 
(iii) otprilike 350 ug tvari od 1 do 2 puta na dan.
A drive gear 84 is coupled to and driven for rotation by the first electric motor 44. 
Pogosnki zupčanik (84) je spojen na elektromotor koji ga rotacijski pokreće.
The solution was filled into 25 ml vials using an automatic pump and silicone platinum-cured tubing 3.2 mm. 
Otopina je napunjena u 25 ml ampule primjenom automatske pumpe i cijevi pod tlakom obrađene silicijem i platinom 3.2 mm.
the medical ophthalmic solution for the use described in any of the above-mentioned (1) to (7), wherein Z represents a phenyl group, thienyl group, imidazolyl group, thiazolyl group, pyridyl group or pyrimidinyl group each of which may be substituted by a group(s) selected from the group consisting of a halogen atom, C1-C4 alkyl group, halogeno C1-C4 alkyl group, C1-C4 alkoxyl group and halogeno C1-C4 alkoxyl group, 
Medicinska oftalmološka otopina za uporabu prema bilo kojem od Zahtjeva 1 do 7, gdje Z predstavlja fenil skupinu, tienil skupinu, imidazolil skupinu, tiazolil skupinu, piridil skupinu ili pirimidinil skupinu od kojih svaka može biti supstituirana skupinom/skupinama izabranim iz grupe koju čine atom halogena, C;-Cy alkil skupina, halogeno Ci-C4 alkil skupina, Ci-C4 alkoksil skupina i halogeno C;-Ca alkoksil skupina.
The method as in embodiment 1, wherein the wear resistant particles (15) are applied in a raster pattern with pre-determined distance (D1, D2) between the wear resistant particles (15). 
Postupak prema zahtjevu 1, naznačen time što je unaprijed određeni uzorak (BP) rasterski uzorak tako da su vezane čestice otporne na habanje raspoređene na međusobno unaprijed određenim udaljenostima (D1, D2).
The composition for use according to claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is administered orally, intravenously, or intraperitoneally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu se terapijski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli daje oralno, intravenozno ili intraperitonealno.
The formulation is sterilized by commonly used techniques. 
Formulacija se sterilizira uobičajenim tehnikama.
The use of claim 5 or 6, wherein donepezil or the pharmaceutically acceptable salt thereof, and 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one, the pharmaceutically acceptable salt thereof, the hydrate thereof or the hydrate of a pharmaceutically acceptable salt thereof are (a) for administration separately to the patient or (b) for administration to the patient in the form of a pharmaceutical composition. 
Upotreba prema zahtjevu 5 ili 6, naznačena time, što se donepezil ili njegova farmaceulski prihvatljiva sol, i 3-(2- cijanofenil)-5-(2-piridil)-1-fenil-1,2-dihidropiridin-2-ona, njegova farmaceutski prihvatljiva sol, njegov hidrat ili hidrat njegove farmaceutski prihvatljive soli (a) daju odvojeno pacijentu ili (b) se daju pacijentu u obliku farmaceutskog pripravka.
SANDING ELEMENT The present invention concerns a sanding element with a succession of overlapping lamellas containing sanding grains, as per the preamble of claim 1. 
Predmetni izum se odnosi na element za brušenje s nizom lamela koje se preklapaju i koje sadržavaju zrnca pijeska, kao što je navedeno u uvodnom dijeli patentnog zahtjeva 1.
or wherein preferably essentially all of the binder part is constituted by waterglass and wherein the waterglass can be supplemented with additives and/or be chemically modified. 
ili pri čemu poželjno je u osnovi vezivni dio u cijelosti sačinjen od vodenog stakla, te pri čemu se vodeno staklo može nadopuniti sa dodacima i/ili može biti kemijski izmijenjeno.
The capture complex of claim 10, wherein the metallic nanoparticle or metallic nanoshell is selected from the group consisting of gold particles, silver particles, copper particles, platinum particles, cadmium particles, composite particles, gold hollow spheres, gold-coated silica nanoshells, and silica-coated gold shells. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što se metalnu nanočesticu ili metalnu nanoljusku bira iz skupine koju čine čestice zlata, čestice srebra, čestice bakra, čestice platine, čestice kadmija, kompozitne čestice, šuplje kuglice od zlata, nanoljuske od silicijevog dioksida obložene zlatom, te zlatne ljuske obložene silicijevim dioksidom.
Proper amount of ethanolamine is weighted into reaction chamber; afterwards ¼ of water is added, followed by quaternary ammonium compound. 
Odgovarajuća količina etanolamina se izvaže u reakcijsku komoru; nakon toga se doda '&A vode, zatim kvat.
The method of claim 22, wherein the E. coli host cell lacks degP and prc genes and harbors a mutant spr gene. 
Postupak prema zahtjevima 5 ili 6, naznačen time, da genotipu bakterije £. coli nedostaju geni degP i prc, ali uzgaja mutirajući gen spr.
moving the laser or electron beam along the surface of the target, such that the plume moves in a radial direction in relation to the rotation axis; 
- < pomicanje lasera ili elektronske zrake duž ciljne površine, tako da se prašina pomiče radijalno u odnosu na rotacijsku os; naznačen time što
The method of claim 7, wherein the cation exchange chromatography is performed with a strong acidic cation exchanger sulfonic acid fixed on a membrane. 
Metoda iz patentnog zahtjeva 7, pri čemu se kationska izmjenjivačka kromatografija provodi jako kiselim kationskim izmjenjivačem sulfonskom kiselinom učvršćenom na membranu, ili izmjenjivačem sličnih karakteristika.
Pharmaceutical composition according to claim 1, wherein the PDE4 inhibitor is ROFLUMILAST-N-oxide. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da PDE4-inhibitor je ROFLUMILAST-N-oksid.
communicatively coupling a first airline remote station (4) to a first interface (35a) of the ground station (35); 
- <- Komunikacijsko uparivanje prve daljinske zrakoplovne postaje (4) s prvim sučeljem (35a) zemaljske postaje
a high-pressure pump configured to compress LNG at a high pressure and supply the compressed LNG to the high-pressure gas injection engine; and 
drugu crpku (4) konfiguriranu da dodatno stlačuje LNG na visoki pritisak i da dobavlja dodatno komprimirani LNG prema visokotlačnom plinskom injekcijskom motoru;
is a cleavable amino group protecting moiety; and 
P' je zaštitna grupa amino grupe koja se može odvojiti; i
The pharmaceutical composition of claim 6, wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Farmaceutska kompozicija prema patentnom zahtjevu 6, naznačena time što su poremećaji 1 bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića induciran pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike i inkontinencija.
IL-2 microaggregates were prepared as described above. 
Mikroagregati IL-2 pripravljeni su kako je gore opisano.
optionally, effecting on the compound prepared according to the step (a): 
(b) prema potrebi, spoj dobiven prema stupnju (a) se podvrgava:
Apparatus according to anyone of the preceding claims, wherein the resin supplying device is configured for supplying liquid synthetic resin comprising at least one active agent at a first concentration, the active agent being one of: 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je uređaj za dostavu smole (18) konfiguriran za dostavu tekuće sintetske smole koja sadrži najmanje jedno aktivno sredstvo u prvoj koncentraciji, gdje je aktivno sredstvo jedno od:
alternatively, R3 and R4 are taken together with the carbon to which they are attached to form a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl; 
alternativno, R3 i R4 su uzeti zajedno s ugljikom na koji su spojeni da tvore C3-10cikloalkilni ili heterocikloalkilni prsten; pri čemu C3-10cikloalkilni ili heterocikloalkilni prsten je nesupstituiran ili supstituiran s -C1-4alkilom ili acetilom;
The compound of any one of claims 1-10, 13-14, and 18-19, having Formula II: or a pharmaceutically acceptable salt thereof. 
Spoj iz bilo kojeg od patentnih zahtjeva 1-10, 13-14 i 18-19 formule II:
A cyclic undecapeptide of the following formula: wherein 
Ciklički undekapeptid sljedeće formule:
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound chlorothalonil. 
CH, naznačen time da je Ry difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj klorotalonil.
During the second treatment period, the dose of the IL-17 antagonist may be reduced while the dose of the IL-23 antagonist is held constant, or the dose of each antagonist may be gradually reduced. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 18, naznačen time, da se doza svakog od IL-17 antagonista i 1L-23 antagonista postupno smanjuje za vrijeme drugog razdoblja liječenja koje započinje završetkom prvog razdoblja liječenja.
More particularly, example embodiments provide a composite material comprising one or more fillers and a polymerizable resin base, wherein said one or more fillers comprise at least one filler ingredient, said filler ingredient(s) being present in a metastable first phase and being able to undergo a martensitic transformation to a stable second phase, the volume ratio between said stable second phase and said metastable first phase of said filler ingredient(s) being at least 1.005. 
Određenije, ovaj izum prikazuje kompozitni materijal koji sadrži jedan ili više punila i bazu za smolu koja polimerizira, pri čemu rečena punila sadrže jedan ili više materijala za punila, a rečeni materijali) za punilo je prisutan u metastabilnoj prvoj fazi koja može proći kroz martenzitsku transformaciju u drugu fazu, a omjer volumena između rečene stabilne druge faze i rečene metastabilne prve faze rečenog materijala za punjenje je najmanje 1.005.
Viscoelastic gels and hydrogels made of autocrosslinked hyaluronic acid (ACP) mixed with hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether, BDDE (HBC) in a weight ratio from 5:95 to 50:50, for use in ophthalmic surgery as antifibrotic gels. 
HR P20150618 T1 PATENTNI ZAHTJEVI Viskoelastični gelovi 1 hidrogelovi naznačeni time da su pripravljeni od samoumrežene hialuronske kiseline (ACP, engl. autocrosslinked hyaluronic acid) s 1,4-butandiol-diglicil-eterom BDDE (HBC) masenih omjera od 5:95 do 50:50, za upotrebu pri operacijama oka kao antifibrotični gelovi.
It was taken up in Pet ether (400mL) and left at 4°C. After 16h the suspension was filtered and washed with Pet ether (2 x 300mL) to give after drying under vacuum the first crop m= 105.76g. 
Otopi se u petroleteru (400 ML) i ostavi pri 4 *C. Nakon 16 h suspenzija se profiltrira i ispere s petroleterom (2x300 mL), te se nakon sušenja pod vakuumom dobije prvi prinos m = 105,76 g.
Some embodiments are "C 1-2 alkylamino." 
Neki oblici su "C1., alkilamino"'.
A therapeutic or prophylactic agent for a gastrointestinal disorder associated with hypomotility, comprising the compound or pharmacologically acceptable salt thereof according to any one of claims 1 to 25 as an active ingredient. 
Lijek prema patentnom zahtjevu 27, za uporabu kao terapeutsko ili profilaktičko sredstvo za gastrointestinalni poremećaj povezan sa hipomotilitetom.
The use of claim 23, wherein said immunogenic composition is effective in the prevention of PCV2 clinical signs and disease manifestations when a PRRS infection is present. 
Uporaba sastava prema zahtjevu 29, naznačena time, da služi u proizvodnji lijeka za prevenciju infekcije s PCV2.
The method of claim 1, wherein said subject has been determined to be affected with a not yet manifested disorder or at risk to develop the disorder by the presence or absence of a surrogate marker selected from the group consisting of old age, and brain amyloid, load. The method claim 1, wherein said disorder is a neurological disorder. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time, da je kod navedenog bolesnika utvrđeno da pati od poremećaja koji se još nije manifestirao ili postoji rizik da bi mogao razviti poremećaj zbog prisutnosti ili odsutnosti surogatnog markera, pri čemu je poželjno da je navedeni surogatni marker odabran iz skupine koja obuhvaća starost, amiloidno opterećenje mozga, ApoE genotip, APP genotip, PSI genotip, razine tjelesnih tekućina Abeta peptida, izoprostan, Tau i fosfo-Tau.
A compound having a structure of formula (II): 
L m Spoj sa strukturom formule (IT):